Associations among Epstein-Barr virus subtypes, human leukocyte antigen class I alleles, and the development of posttransplantation lymphoproliferative disorder in bone marrow transplant recipients

Clinical Infectious Diseases

Volumn 44, Issue 5, 2007, Pages 693-695

  Görzer, Irene ^a   Puchhammer Stöckl, Elisabeth ^a   Van Esser, Joost W J ^b   Niesters, Hubert G M ^b   Cornelissen, Jan J ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; HLA B51 ANTIGEN;

ADULT; ALLELE; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; GENETIC ASSOCIATION; GRAFT RECIPIENT; HUMAN; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; VIRUS STRAIN;

ALLELES; BONE MARROW TRANSPLANTATION; EPSTEIN-BARR VIRUS INFECTIONS; GENETIC PREDISPOSITION TO DISEASE; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33847008323     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511647     Document Type: Article

References (19)

1. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995; 59:387-405.
2. Davis JE, Moss DJ. Treatment options for posttransplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 2004; 63:285-92.
3. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant; an approach in development. Bone Marrow Transplant 2006; 37:539-46.
4. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94:2208-16.
5. Sandvej K, Gratama JW, Munch M, et al. Sequence analysis of the Epstein-Barr virus (EBV) latent membrane protein-1 gene and promoter region: identification of four variants among wild-type EBV isolates. Blood 1997; 90:323-30.
6. Görzer I, Niesters HG, Cornelissen JJ, Puchhammer-Stöckl E. Characterization of Epstein-Barr virus type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes. Virus Res 2006; 118:105-14.
7. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000; 38:712-5.
8. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98:972-8.
9. Knowles D, Cesarman ME, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85:552-65.
10. Sample J, Young L, Martin B, et al. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990; 64:4084-92.
11. Heslop HE, Rooney CM. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 1997; 157:217-22.
12. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr virus-negative Hodgkin's lymphoma. Lancet 2005; 365:2216-24.
13. Mizuki N, Ota M, Katsuyama Y, et al. Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 1999; 42:1961-6.
14. Maenaka K, Maenaka T, Tomiyama H, Takiguchi M, Stuart DI, Jones EY. Nonstandard peptide binding revealed by crystal structures of HLA-B*5101 complexed with HIV immunodominant epitopes. J Immunol 2000;165:3260-7.
15. Hill A, Takiguchi M, McMichael A. Different rates of HLA class I molecule assembly which are determined by amino acid sequence in the alpha 2 domain. Immunogenetics 1993; 37:95-101.
16. Sakaguchi T, Ibe M, Miwa K, et al. Binding of 8-mer to 11-mer peptides carrying the anchor residues to slow assembling HLA class I molecules (HLA-B*5101). Immunogenetics 1997; 45:259-65.
17. Rammensee HG, Bachmann J, Emmerich NN, Bachor OA, Stevanovic S. SYFPEITHI: database of MHC ligands and peptide motif. Immunogenetics 1999; 50:213-9. Available at: http://www.syfpeithi.de/. Accessed 31 August 2006.
18. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163. Available at: http://thr.cit.nih.gov/molbio/ hla_bind/. Accessed 31 August 2006.
19. Moss DJ, Burrows SR, Silins SL, Misko I, Khanna R. The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci 2001; 356:475-88.